Stomach Cancer Clinical Trial
— PETRARCAOfficial title:
FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO.
Verified date | August 2020 |
Source | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in the perioperative treatment of resectable HER-2 positive adenocarcinoma of the stomach or GEJ.
Status | Completed |
Enrollment | 81 |
Est. completion date | July 17, 2020 |
Est. primary completion date | July 17, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the GEJ (type I-III) or the stomach (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications: - Medical and technical operability - Centralized detection of either an adenocarcinoma with HER-2 3+ (IHC) or HER-2 2+ (IHC) with amplification proven by FISH, SISH or CISH 2. No preceding cytotoxic or targeted therapy 3. No prior partial or complete tumor resection 4. Exclusion of the infiltration of any adjacent organs or structures by CT or MRI 5. Exclusion of distant metastasis by CT or MRI of thorax and abdomen, and bone scan (if osseous lesions are suspected due to clinical signs) 6. Female and male patients = 18 years. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of pertuzumab and Herceptin treatment (Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start. 7. ECOG = 2 8. Laparoscopic exclusion of peritoneal carcinomatosis, if suspected clinically 9. Adequate haematological, hepatic and renal function parameters: - Leukocytes = 3.000/mm³, platelets = 100.000/mm3 - Serum creatinine = 1.5 x upper limit of normal, or GFR > 40 ml/min - Bilirubin = 1.5 x upper limit of normal, AST and ALT = 3.5 x upper limit of normal, alkaline phosphatase = 6 x upper limit of normal 10. LVEF value > 55 %, as assessed by echocardiography 11. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures Exclusion Criteria: 1. Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastasis!) 2. Known hypersensitivity against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel 3. Other known contraindications against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel 4. Documented history of congestive heart failure of any NYHA, myocardial infarction within the past 6 months before the first dose of study treatment 5. Clinically significant valvular defect , history of poorly controlled arterial hypertension (systolic blood pressure > 180 mmHG or diastolic blood pressure > 100 mmHg) or uncontrollable high-risk cardiac arrhythmia (i.e tachycardia with a heart rate > 100/min at rest), significant ventricular arrhythmia (ventricular tachycardia) or higher grade atrioventricular-block (second degree AV-block Type 2 (Mobitz2) or third degree AV-block) 6. Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix 7. Known brain metastases 8. Other severe internal disease or acute infection 9. Peripheral polyneuropathy = NCI Grade II 10. Chronic inflammatory bowel disease 11. Clinically significant active GI bleeding 12. On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study 13. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. 14. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4) 15. Any other concurrent antineoplastic treatment including irradiation |
Country | Name | City | State |
---|---|---|---|
Germany | Institute for Clinical Cancer Research Krankenhaus Nordwest | Frankfurt |
Lead Sponsor | Collaborator |
---|---|
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trium Analysis Online GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PhaseII: Rate of pathological complete response | 3 years | ||
Primary | Phase III: Median Progression Free Survival | 5 years | ||
Secondary | Phase II/III: R0 resection rate | 75 days | ||
Secondary | Phase II: Median Progression Free Survival (PFS) | 3 years | ||
Secondary | Phase II/III: Median Overall Survival | 3/5 years | ||
Secondary | Phase II: PK Analysis | 3 years | ||
Secondary | Phase II/III: Subgroup analyses: pathological response according to HER-2 status HER-2 IHC 3+ vs. other cases | 3/5 years | ||
Secondary | Phase II/III: Subgroup analyses: PFS according to HER-2 status HER-2 IHC 3+ vs. other cases | 3/5 years | ||
Secondary | Phase II/III: Subgroup analyses: OS according to HER-2 status HER-2 IHC 3+ vs. other cases | 3/5 years | ||
Secondary | Phase III: Pathological Response Rates | 5 years | ||
Secondary | Phase III: PFS rates | 3 and 5 years | ||
Secondary | Phase III: OS rates | 3 and 5 years | ||
Secondary | Phase III: Median OS | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT02604979 -
The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study
|
N/A | |
Active, not recruiting |
NCT00394433 -
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
|
Phase 2 | |
Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
Completed |
NCT00215514 -
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 0 | |
Recruiting |
NCT04486651 -
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT05415475 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04526470 -
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01257711 -
A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
|
N/A | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Withdrawn |
NCT03704077 -
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05489250 -
The PLATON Network
|
||
Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
Completed |
NCT02547064 -
Effect of Modified Stylet Angulation on the Intubation With GlideScope®
|
N/A | |
Withdrawn |
NCT00800969 -
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
|
Phase 2 | |
Completed |
NCT00296322 -
Trial of Adjuvant Chemotherapy for Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT04215861 -
Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy
|
||
Recruiting |
NCT06199895 -
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
|
Phase 2 | |
Recruiting |
NCT01038154 -
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
|
Phase 4 |